<DOC>
	<DOCNO>NCT02627417</DOCNO>
	<brief_summary>Due expect efficacy base retrospective data available ITP , relatively good safety profile low cost , dapsone could good steroid-sparing second-line option adult ITP . This study phase III prospective multicenter randomize open trial compare two treatment strategy : - Arm A ( experimental arm ) : prednisone 1 mg/kg 3 week + dapsone 100 mg per day week 52 initial response achieve . - Arm B ( control arm ) : prednisone alone 1 mg/kg 3 week follow monitor `` standard care '' The aim study demonstrate efficacy dapsone base overall response rate ( include response complete response ) second-line treatment adult newly-diagnosed persistent ITP achieve durable response corticosteroid . The primary endpoint overall response-rate ( response complete response accord standard definition ) arm week 52 ( 1 year ) . The secondary endpoint follow : - To assess safety dapsone study period especially incidence cutaneous reaction . - To analyze overall response rate ( platelet count &gt; 30 x 109/L least double pre-treatment count absence ITP treatment ) treatment arm week 24 . - To compare rate complete response failure arm 24 52 week . - To compare time treatment failure ( TTF ) arm - To investigate mechanism action dapsone ITP subgroup patient ( ancillary study )</brief_summary>
	<brief_title>Efficacy Safety DAPSone Second-line Option Adult Immune Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Age ≥ 18 year Diagnosis primary ITP accord standard definition international guideline . Previous transient response corticosteroid ± intravenous immunoglobulin define increase platelet count 30 x 109/L least twofold increase pretreatment count . Disease duration le 12 month . Platelet count ≤ 30 x 109/L inclusion &lt; 50 x 109/L patient require treatment Normal marrow aspirate patient age 60 . Negative pregnancy test effective method contraception woman childbearing age study period . Informed consent . Patient affiliate French National Social Security System Secondary ITP . Patients positive antinuclear antibody and/or positive antiphospholipid antibody fulfil classification criterion systemic lupus erythematosus and/or antiphospholipid antibody syndrome exclude . Chronic ITP ( i.e , disease duration &gt; 12 month ) . Platelet count &gt; 50 x 109/L 30 50 x 109/L bleeding symptom and/or need treatment Severe bleed manifestation define bleed score ≥ 8 No previous transient response corticosteroid ± intravenous immunoglobulin . Previous ITP treatment corticosteroid intravenous immunoglobulin ( include rituximab splenectomy ) . Active severe infection history severe infection within 4 week inclusion . History allergy sulfonamide . Glucose6phosphate dehydrogenase ( G6PD ) deficiency . History methemoglobinemia Hemoglobin level &lt; 11g/dL and/or neutrophil count &lt; 1,500/ gL . History autoimmune ( Evans ' syndrome ) hereditary haemolytic anemia . Liver kidney function impairment ( creatinine , ALT , AST &gt; 2 time upper normal limit ) . Hepatitis C virus ( HCV ) Ab , HIV Ab , HBsAg , HBcAb seropositive status . Concomitant medical condition require aspirin and/or clopidogrel intake anticoagulation . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>ITP</keyword>
	<keyword>Dapsone</keyword>
</DOC>